Stephen 205 (1)

Online Published (2011) ISSN: 0976-7908 Selvan et al

PHARMA SCIENCE MONITOR
AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES

REVIEW ON IMPURITIES: A REGULATORY OVERVIEW
M.Arulselvan1*, B.Stephen Rathinaraj2,Sirajudeen.M.A.3, Md. Fareedullah2, Farsiya
Fatima2, Fatima Shiree2
1
Department of Pharmaceutical Analysis, Oriental College of Pharmacy.Navi Mumbai,India.
Mumbai,India
2
Department of Pharmaceutics, Vaagdevi College of Pharmacy, Hanamkonda, Warangal, Andhrapradesh,
India.
3
Department of Pharmaceutical Biotechnology, Omega College of Pharmacy, Hyderabad, Andhrapradesh,
India
ABSTRACT
Increasing demands of consumers and higher competition in the market emphasize the
importance of drug analysis. The accurate assessment of quality and freshness is
especially important to ease anxiety and to benefit consumers. The quality and stability of
pharmaceutical substances can be affected by the presence of volatile impurities. Volatile
impurities in pharmaceutical products are often residual solvents used in the synthesis,
crystallization that escapes during drying or in extraction. This paper reviews the residual
solvents found in the pharmaceuticals, identifying different sources, as well as providing
examples and demonstrating possible measures regarding the control of these organic
volatile impurities in pharmaceuticals.
Keywords: Residual solvents; sources of residual solvents; ICH guideline; analysis of
residual solvents.
INTRODUCTION
Residual solvents in pharmaceuticals, commonly known as organic volatile
impurities (OVIs), are chemicals that are either used or produced during the manufacture
of active pharmaceutical ingredients (APIs), excipients and drug products [1, 2].
Organic solvents play an essential role in drug-substance and excipient
manufacture (e.g., reaction, separation and purification) and in drug-product formulation
[3]
(e.g., granulation and coating) . Some organic solvents are often used during the
synthesis of active pharmaceutical ingredients and excipients or during the preparation of
[2]
drug products to enhance the yield, increase solubility or aid crystallization . These

www.pharmasm.com IC Value – 4.01 1756


process solvents cannot be completely removed by practical manufacturing practices such
as freeze–drying and drying at high temperature under vacuum. Therefore, some residual
solvents may remain in drug substance material4. Typically, the final purification step in
many pharmaceutical drug-substance processes involves a crystallization step, and the
crystals thus formed can entrap a finite amount of solvent from the mother liquor that
may cause degradation of the drug, OVIs may also contaminate the products during
packaging, storage in warehouses and/or during transportation.[3]

Sources of residual solvents

Used as vehicle Dissolution during Used during
during synthesis purification or granulation, coating
may remain as crystallization may or any other unit
residue remain as residue operation

Figure 1
Sources of residual solvents

While solvents play a key role in the production of pharmaceuticals, there is also
a downside, as many of the solvents used have toxic or environmentally hazardous
properties. Complete removal of residual levels of solvents is impractical from a
manufacturing standpoint, so it is inevitable that traces will remain in the final product.
The presence of these unwanted chemicals even in small amounts may influence the
efficacy, safety and stability of the pharmaceutical products. Because residual solvents
have no therapeutic benefits but may be hazardous to human health and the environment,
it must be ensured that they are either not present in products or are only present below
recommended acceptable levels. It is a drug manufacturer's responsibility to ensure that
any OVIs present in the final product are not harmful to humans and that medicinal
products do not contain levels of residual solvents higher than recommended safety
limits. Solvents known to cause unacceptable toxicity should be avoided unless their use



can be justified on the basis of a risk--benefit assessment2. Because of their proven or
potential toxicity the level of residual solvents is controlled through national and
international guidelines, for example through the FDA and International Conference on
Harmonization.
"All drug substances, excipients, and products are subject to relevant control of
residual solvents, even when no test is specified in the individual monograph."
REGULATORY AND COMPLIANCE ENVIRONMENT:
One of the essential aspects of pharmaceutical manufacturing is regulatory
compliance, which typically encompasses two aspects. The first is compliance with
private sets of standards based on an applicant filing with a regulatory agency, which
requires the applicant to report the determined residual solvent levels in a number of
representative batches of pharmaceutical product to establish typical levels of solvent
contamination that can routinely be achieved. Based on a statistical evaluation of the
reported data, a specification is agreed for solvents used in the final step of the process
and a decision made on whether testing is required for solvent used at earlier stages in the
process. To arrive at a specification that is a measure of the routine performance of the
process, regulatory agencies require numerical data rather than reporting compliance with
a limit test.
Internationally, there has been a need to establish regulatory standard guidelines.
In 1997, The International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH), through its Q3C Expert working
group formed by regulators from the three ICH regions, industry representatives and
interested parties/observers, finalized the Q3C guideline on residual solvents. Essentially,
ICH has consistently proposed that limits on organic solvents be set at levels that can be
justified by existing safety and toxicity data, and also kept proposed limits within the
level achievable by normal manufacturing processes and within current analytic
capabilities.
The second aspect is compliance with public standards set by Pharmacopoeias
from the three ICH regions (United States Pharmacopoeia (USP), European
Pharmacopoeia (Ph. Eur.) and Japanese Phamacopoeia (JP)) and also with local
pharmacopoeias from countries outside the ICH regions. In the recent past, guidelines for



organic residual solvents for public standards have generally been vague and not up to
date. The pharmacopoeial approach was typically a limit test for residual solvents,
employing standard addition[3]. The USP set the official limits in USP 23rd edition in the
general chapter<467> organic volatile impurities5. Very early on, the Ph. Eur. employed
the ICH Q3C regulatory approach and updated the acceptance limits but kept the
methodology as a limit test based on standard addition. The general method in Ph. Eur.
for Identification and Control of Residual Solvents in drug substances defines a general
procedure and describes two complementary gas chromatography (GC) conditions for
identifying unknown solvents. ‘‘System A’’ is recommended for general use and is
equivalent to ‘‘Methods IV and V’’ of the USP for analysis of volatile organic impurities
‘‘System B’’ is used to confirm identification and to solve co-elutions. Implementation of
this general method is a subject of debate in the pharmaceutical industry due to its limited
selectivity and sensitivity3. Historically, until its 27th edition, the USP restricted its
listing of residual solvents to those of Class 1 and neglected to consider the wide range of
organic solvents used routinely in the pharmaceutical industry. Furthermore, the limits
stated for Class 1 solvents benzene, chloroform, 1, 4-dioxane, methylene chloride, and 1,
1, 1-trichloroethane are in the range 2–600 (ppm) and are therefore not in concordance
with the ICH guideline. Residual solvent testing using GC has been included in the
pharmacopeias for almost 20 years, while residual solvent-test methods have been
reported in the literature since before that. With USP 28, the public standard for residual
solvents was updated to comply with the ICH Q3C guideline, but the methodology (the
same limit-test approach as Ph. Eur.) and the targeted monographs were not considered
appropriate by industry and regulators, leading to a notice postponing implementation in
USP 29 [6].
ICH GUIDELINE:
The objective of this guidance is to recommend acceptable amounts for residual
solvents in pharmaceuticals for the safety of the patient. The guidance recommends use
of less toxic solvents and describes levels considered to be toxicologically acceptable for
some residual solvents.
Residual solvents in pharmaceuticals are defined here as organic volatile
chemicals that are used or produced in the manufacture of drug substances or excipients,



or in the preparation of drug products. This guidance does not address solvents
deliberately used as excipients nor does it address solvates. However, the content of
solvents in such products should be evaluated and justified.
Since there is no therapeutic benefit from residual solvents, all residual solvents
should be removed to the extent possible to meet product specifications, good
manufacturing practices, or other quality-based requirements. Drug products should
contain no higher levels of residual solvents than can be supported by safety data. Some
solvents that are known to cause unacceptable toxicities (Class 1) should be avoided in
the production of drug substances, excipients, or drug products unless their use can be
strongly justified in a risk-benefit assessment. Some solvents associated with less severe
toxicity (Class 2) should be limited in order to protect patients from potential adverse
effects. Ideally, less toxic solvents (Class 3) should be used where practical [7].
SCOPE OF THE GUIDANCE:
Residual solvents in drug substances, excipients, and drug products are within the
scope of this guidance. Therefore, testing should be performed for residual solvents when
production or purification processes are known to result in the presence of such solvents.
It is only necessary to test for solvents that are used or produced in the manufacture or
purification of drug substances, excipients, or drug products. Although manufacturers
may choose to test the drug product, a cumulative method may be used to calculate the
residual solvent levels in the drug product from the levels in the ingredients used to
produce the drug product. If the calculation results in a level equal to or below that
recommended in this guidance, no testing of the drug product for residual solvents need
be considered. If, however, the calculated level is above the recommended level, the drug
product should be tested to ascertain whether the formulation process has reduced the
relevant solvent level to within the acceptable amount. Drug product should also be tested
if a solvent is used during its manufacture.
This guidance does not apply to potential new drug substances, excipients, or drug
products used during the clinical research stages of development, nor does it apply to
existing marketed drug products.
The guidance applies to all dosage forms and routes of administration. Higher
levels of residual solvents may be acceptable in certain cases such as short-term (30 days



or less) or topical application. Justification for these levels should be made on a case-by-
case basis [7].
CLASSIFICATION OF RESIDUAL SOLVENTS:
OVIs are classified into three classes on the basis of their toxicity level and the
degree to which they can be considered an environmental hazard. The list provided in the
guideline is not exhaustive, and one should evaluate the synthesis and manufacturing
processes for all possible residual solvents.
The term tolerable daily intake (TDI) is used by the International Program on
Chemical Safety (IPCS) to describe exposure limits of toxic chemicals and the term
acceptable daily intake (ADI) is used by the World Health Organization (WHO) and
other national and international health authorities and institutes. The new term permitted
daily exposure (PDE) is defined in the present guidance as a pharmaceutically acceptable
intake of residual solvents to avoid confusion of differing values for ADI's of the same
substance [7].
Residual solvents are classified on the basis of risk assessment:
Class 1 solvents: Solvents to be avoided-
Known human carcinogens, strongly suspected human carcinogens, and
environmental hazards.
Class 2 solvents: Solvents to be limited-
Nongenotoxic animal carcinogens or possible causative agents of other
irreversible toxicity such as neurotoxicity or teratogenicity.
Class 3 solvents: Solvents with low toxic potential-
Solvents with low toxic potential to man; no health-based exposure limit is
needed. Class 3 solvents have PDE's of 50 milligrams (mg) or more per day.
Class 4 solvents: Solvents for which no adequate toxicological data was found
No adequate toxicological data on which to base a PDE (permitted dose
exposure) was found [7].
ENVIRONMENTAL REGULATION OF ORGANIC VOLATILE SOLVENTS
Several of the residual solvents frequently used in the production of
pharmaceuticals are listed as toxic chemicals in Environmental Health Criteria (EHC)
monographs and in the Integrated Risk Information System (IRIS). The objectives of



such groups as the International Programme on Chemical Safety (IPCS), the U.S.
Environmental Protection Agency (EPA), and the U.S. Food and Drug Administration
(FDA) include the determination of acceptable exposure levels. The goal is protection of
human health and maintenance of environmental integrity against the possible deleterious
effects of chemicals resulting from long-term environmental exposure. The methods
involved in the estimation of maximum safe exposure limits are usually based on long-
term studies. When long-term study data are unavailable, shorter term study data can be
used with modification of the approach such as use of larger safety factors. The approach
described therein relates primarily to long-term or lifetime exposure of the general
population in the ambient environment (i.e., ambient air, food, drinking water, and other
media) [7].
LIMITS OF RESIDUAL SOLVENTS:
A. Solvents to Be Avoided
Solvents in Class 1 (Table 1) should not be employed in the manufacture of drug
substances, excipients, and drug products because of their unacceptable toxicity or their
deleterious environmental effect. However, if their use is unavoidable in order to produce
a drug product with a significant therapeutic advance, then their levels should be
restricted as shown in Table 1, unless otherwise justified. The solvent 1, 1, 1-
Trichloroethane is included in Table 1 because it is an environmental hazard. The stated
limit of 1,500 ppm is based on a review of the safety data.
TABLE 1: CLASS 1 SOLVENT (SOLVENTS THAT SHOULD BE AVOIDED)
Concentration limit Concern
(ppm)
Benzene 2 Carcinogen
Carbon tetrachloride 4 Toxic and
environmental
hazard
1,2-Dichloroethane 5 Toxic
1,1 - Dichloroethane 8 Toxic
1,1,1 - Trichloroethane 1500 Environmental hazard

B. Solvents to Be Limited
Solvents in Class 2 (Table 2) should be limited in pharmaceutical products
because of their inherent toxicity. PDEs are given to the nearest 0.1 mg/day, and



concentrations are given to the nearest 10 ppm. The stated values do not reflect the
necessary analytical precision of determination. Precision should be determined as part of
the validation of the method [7].
TABLE 2: CLASS 2 SOLVENTS (SOLVENTS TO BE LIMITED)
Solvent PDE (mg/day) Concentration limit
(ppm)
Acetonitrile 4.1 410
Chlorobenzene 3.6 360
Chloroform 0.6 60
Cyclohexane 38.8 3880
1,2-Dichloroethane 18.7 1870
Dichloromethane 6.0 600
1,2-Dimethoxyethane 1.0 100
N,N-Dimethylacetamide 10.9 1090
N,N-Dimethylformamide 8.8 880
1,4-Dioxane 3.8 380
2-Ethoxyethanol 1.6 160
Ethyleneglycol 6.2 620
Formamide 2.2 220
Hexane 2.9 290
Methanol 30.0 3000
2-Methoxyethanol 0.5 50
Methylbutyl ketone 0.5 50
Methylcyclohexane 11.8 1180
N-Methylpyrrolidone 48.4 4840
Nitromethane 0.5 50
Pyridine 2.0 200
Sulfolane 1.6 160
Tetralin 1.0 100
Toluene 8.9 890
1,1,2-Trichloroethene 0.8 80
Xylene* 21.7 2170
* Usually 60% m-xylene, 14% p-xylene, 9% o-xylene with 17% ethyl benzene
C. Solvents with Low Toxic Potential
Solvents in Class 3 (Table 3) may be regarded as less toxic and of lower risk to
human health. Class 3 includes no solvent known as a human health hazard at levels
normally accepted in pharmaceuticals. However, there are no long-term toxicity or
carcinogenicity studies for many of the solvents in Class 3. Available data indicate that
they are less toxic in acute or short-term studies and negative in genotoxicity studies. It is
considered that amounts of these residual solvents of 50 mg per day or less



(corresponding to 5,000 ppm or 0.5 percent under Option 1) would be acceptable without
justification. Higher amounts may also be acceptable provided they are realistic in
relation to manufacturing capability and good manufacturing practice (GMP) [7].
D. Solvents for which no adequate toxicological data were found
The solvents listed in Table 4 may also be of interest to manufacturers of
excipients, drug substances, or drug products. However, no adequate toxicological data
on which to base a PDE were found. Manufacturers should supply justification for
residual levels of these solvents in pharmaceutical products[7].
TABLE 3: CLASS 3 SOLVENTS (SOLVENTS WITH LOW TOXIC POTENTIAL)
 Acetic acid  Heptane
 Acetone  Isobutyl acetate
 Anisole  Isopropyl acetate
 1-Butanol  Methyl acetate
 2-Butanol  3-Methyl-1-butanol
 Butyl acetate  Methylethyl ketone
 tert-Butylmethyl ether  Methylisobutyl ketone
 Cumene  2-Methyl-1-propanol
 Dimethyl sulfoxide  Pentane
 Ethanol  1-Pentanol
 Ethyl acetate  1-Propanol
 Ethyl ether  2-Propanol
 Ethyl formate  Propyl acetate
 Formic acid  Tetrahydrofuran

TABLE 4: SOLVENTS FOR WHICH NO ADEQUATE TOXICOLOGICAL
DATA WERE FOUND
 1,1-Diethoxypropane
 1,1-Dimethoxymethane
 2,2-Dimethoxypropane
 Isooctane
 Isopropyl ether
 Methylisopropyl ketone
 Methyltetrahydrofuran
 Petroleum ether
 Trichloroacetic acid
 Trifluoroacetic acid



THE CURRENT STATUS OF USP, EP AND JP:
Although the ICH guideline regarding residual solvents in pharmaceuticals
became official in July 1997, USP has not fully adopted it. The current status of each
pharmacopeia is different [2].
United States Pharmacopoeia (USP):
In 1988, the United States Pharmacopoeia (USP) provided control limits and
testing criteria for seven organic volatile impurities (OVIs) under official monograph
[8]
<467> . According to USP, testing should be conducted only if a manufacturer has
indicated the possible presence of a solvent in a product. Testing may be avoided when a
manufacturer has assurance, based on the knowledge of the manufacturing process and
controlled handling, shipping, and storage of the product, that no potential exists for
specific solvents to be present and that the product, if tested, will comply with the
accepted limit. Items shipped in airtight containers (such as those used for food additives)
can be considered not to have acquired any solvents during transportation [2]. USP <467>
recommends testing for seven organic volatile impurities is listed in Table 5 [9].
TABLE 5: ORGANIC VOLATILE IMPURITIES (OVI)
OVI Limit
Benzene 2 ppm max
Chloroform 60 ppm max
1, 4-Dioxane 380 ppm max
Methylene Chloride 600 ppm max
Trichloroethylene 80 ppm max

The compounds were chosen based on relative toxicity and only applied to drug
[8]
substances and some excipients . In addition; a test for ethylene oxide is conducted if
specified in the individual monograph. Unless otherwise specified in the individual
monograph, the acceptable limit for ethylene oxide is 10 ppm. USP does not address all
other solvents mentioned in the ICH guideline [2].
In an effort to harmonize with the International Conference for Harmonization
(ICH), the USP has proposed the adoption of a slightly modified version of ICH (Q3C)
methodology, which has been scheduled for implementation on July 1, 2007. The ICH



Q3C methodology provides a risk-based approach to residual solvent analysis that
considers a patient’s exposure to a solvent residue in the drug product. Solvents have
been classified based on their potential health risks into three main classes:
• Class 1: Solvents should not be used because of the unacceptable toxicities or
deleterious environmental effects
• Class 2: Solvents should be limited because of inherent toxicities
• Class 3: Solvents may be regarded as less toxic and of lower risk to human health
Testing is only required for those solvents used in the manufacturing or
purification process of drug substances, excipients, or products. This allows each
company to determine which solvents it uses in production and develop testing
procedures that address their specific needs. It is the responsibility of the drug
manufacturer to qualify the purity of all the components used in the manufacturing of the
drug product. This would pertain to items such as excipients, of which some contain
residual levels of Class 1 solvents by nature of the manufacturing process and/or nature
of the starting materials (e.g. ethyl cellulose). The new <467> monograph provides an
optional method to determine when residual solvent testing is required for Class 2
solvents. Each Class 2 solvent is assigned a permitted daily exposure (PDE) limit, which
is the pharmaceutically acceptable intake level of a residual solvent.
The USP has provided a method for the identification, control, and quantification
of Class 1 and 2 residual solvents. The method calls for a gas chromatographic (GC)
analysis with flame ionization detection (FID) and a headspace injection from either
water or organic diluent. The monograph has suggested two procedures: Procedure A
G43 (Zebron ZB-624) phase and Procedure B G16 (Zebron ZB-WAXplus) phase.
Procedure A should be used first. If a compound is determined to be above the specified
concentration limit, then Procedure B should be used to confirm its identity. Since there
are known co-elutions on both phases, the orthogonal selectivity ensures that co-elutions
on one phase will be resolved on the other. Neither procedure is quantitative, so to
determine the concentration the monograph specifies Procedure C, which utilizes
whichever phase will give the fewest co-elutions. Class 3 solvents may be determined by
<731> Loss on Drying unless the level is expected to be >5000 ppm or 50 mg. If the loss



on drying is >0.5 %, then a water determination should be performed using <921> Water
Determination.
One of the most important considerations is that once implemented, the new
method will pertain to all currently marketed drug products as well as those in
development and clinical trials [8].
European Pharmacopoeia (EP):
EP has fully adopted the ICH guideline regarding residual solvents in 1997. In
2000, they started requiring that all currently marketed drug products, as well as those in
development or clinical trial, meet the ICH guidelines [8]. Section 2.4.24 of the 4th edition
of EP describes how to identify and quantify Class 1 and Class 2 residual solvents. The
test methods can be used to identify the majority of Class 1 and Class 2 solvents when
they are unknown and as limit tests for Class 1 and Class 2 solvents. The methods also
can be used for the quantification of Class 2 solvents when the limits are ≥ 1000 ppm
(0.1%) or for the quantification of Class 3 solvents when required [2].
In 2005 (EP 5th edition) it has been agreed that acceptance criteria for Class II
solvents would not be mentioned in the European Pharmacopoeia monographs and that
Class I solvents would be included only where it was known that their use was
unavoidable in the manufacturing process for the drug substance using the acceptance
criteria laid down in the ICH guidelines. Finally, it is also recognized that some specific
substances produce solvated forms for which there are frequently higher levels of
solvents, for example, Class III solvents co-crystallising with the active substances for
which higher limits than the normal general 0.5% limit may have to be applied. These
higher-level Class III solvents would then be named individually on a case-by-case basis
where their presence at such levels is considered to be unavoidable. It should be stressed
that there is no safety issue relating to such levels since they are low toxicity solvents and
the 0.5% threshold is merely a nominal limit [12].
Japanese Pharmacopoeia (JP):
The current JP (14th) has adopted the ICH guideline. This pharmacopeia defines
residual solvents as those residual organic solvents in pharmaceuticals that should be
tested using gas chromatography to comply with the limits specified in the ICH
Harmonized Tripartite Guideline [2,13].



CASE STUDIES: LIMITS OF RESIDUAL SOLVENT PRESENT IN PFIZER
PRODUCTS AS COMPARED TO ICH LIMITS
Product (Pfizer centre source)
Triamcinolone USP

C21H27FO6 MW 394.43

Organic Volatile Impurities
Of the solvents targeted in USP 26 General Chapter <467>, only methylene
chloride may appear in bulk pharmaceutical products manufactured by Pfizer at the
Kalamazoo plant. For those products where OVI testing is required, our material will
meet the compendial limits for methylene chloride and other solvents that may be added
to the target list in the future.
No OVI requirement exists in the USP 26 monograph for Triamcinolone, but
Triamcinolone from Pfizer meets the requirements of USP 26 General Chapter <467>
[14]
.
ICH Residual Solvents
As of 01 July 2000, Pfizer’s laboratories began to internally report all solvents
that are present above the assay detection limit. During the review of the batch data, it is
verified that no solvents are present above the ICH limits. Therefore, all lots of
Triamcinolone released after 01 July 2000 will meet the ICH residual solvent guidance.
A Comparison of residual solvents content reported by Pfizer and ICH Guideline is listed
in Table 6 [14].



TABLE 6: COMPARISON OF RESIDUAL SOLVENTS CONTENT REPORTED
BY PFIZER AND ICH GUIDELINE
Solvent Pfizer specification* ICH class and specification
Residual solvents (total) NMT 0.5%
Ethyl acetate No individual specification 3 / NMT 0.5%
Methylene chloride NMT 600 ppm 2 / NMT 600 ppm
Tetrahydrofuran No individual specification 3 / NMT 0.5%
 Pfizer does not have Registered Specifications for residual solvents, only quality controls Targets.

ANALYSIS OF RESIDUAL SOLVENT IN PHARMACEUTICALS:
The analysis of residual solvents is an essential part in the quality control of drug
substances used in preclinical or clinical trials as well as for use in commercial drug
products. Residual solvent analysis of bulk drug substance and finished pharmaceutical
products is necessary for a number of reasons:
 High levels of residual organic solvents represent a risk to human health because
of their toxicity
 Residual organic solvents also play a role in the physicochemical properties of the
bulk drug substance. Crystallinity of the bulk drug substance can be affected.
Differences in the crystal structure of the bulk drug may lead to changes in
dissolution properties and problems with formulation of the finished product.
 Finally, residual organic solvents can create odor problems and color changes in
the finished product and, thus, can lead to consumer complaints [5].
 Often, the main purpose for residual solvent testing is in its use as a monitoring
check for further drying of bulk pharmaceuticals or as a final check of a finished
product.
 Testing for solvent content in intermediates may need to be performed if a critical
amount of residual solvent(s) remaining in the intermediate can alter the next step
of the process.
 Knowledge of the solvent content in the starting materials may help to the
development chemist to understand the synthetic routes and predict potential
process related impurities.



 Knowing the solvents used in the process allows the development chemist to look
for possible compound- solvent interactions which can lead to the formation of
impurities[15].
TABLE 7: LIST OF PHARMACEUTICAL SAMPLE NAMES AND CONTAINED
RESIDUAL SOLVENTS [16].
Pharmaceutical sample Residual solvent Class
Lidocain Heptane 3
Ethyl aminoben Toluene 2
Antipyrine Methanol 2
Phenacetin Methanol, toluene 2, 2
Cimetidine Ethanol 3
Famotidine Methanol 2
carbamazepine Acetone 3

Residual solvent analysis can be performed with a large array of analytical
[17]
techniques . The most popular, and the most appropriate, specific solvent analysis is
testing by gas chromatography (GC). Modern capillary-column gas chromatographs can
separate a large number of volatile components, permitting identification through
retention characteristics and detection at ppm levels using a broad range of detectors
[5]
.Gas chromatographic testing can be categorized into three main procedures according
to the means of introducing the sample into the instrument. A direct gas chromatographic
procedure is one in which a portion of the actual drug substance or formulation is injected
into a GC system. The drug substance is usually dissolved in an appropriate solvent and
loaded into a syringe and injected. Headspace analysis, on the other hand, is an indirect
testing procedure. The analysis is conducted when a volume of gas above the drug
substance or formulation is collected and analyzed by a gas chromatograph. Finally,
solid-phase microextraction (SPME) is making much progress in recent years for residual
solvent testing. In SPME, a silica fiber coated with a sorbent is used to collect and
concentrate the volatile solvents. The volatiles are then thermally desorbed in the inlet of
the gas chromatograph and analyzed [18].



Many alternatives to gas chromatography have been used to determine the level of
residual solvent in pharmaceutical products. Many of these procedures are either
nonspecific—that is, the solvents are not identified—or they have high detection limits,
so they are inappropriate for the detailed product characterization required for a
regulatory submission. The oldest and simplest method for determining the quantity of
volatile residue is measuring the weight loss of a sample during heating. LOD method is
widely used, particularly for Class 3 solvents, due to its simplicity and ease of
introduction into even the most basic analytical laboratory [5]. Another approach is to use
thermogravimetric analysis (TGA), which is a well-known method for the quantitative
[18]
analysis of the loss of volatile components from a sample . Spectroscopic and
spectrometric methods have generally lacked the low detection limits needed for toxic
residual solvents, although the detection limits would be applicable for ICH class 2 and 3
solvents. In the case of infrared spectroscopy (IR), a detection limit above 100 ppm and
lack of accuracy at low concentrations of residual solvent have been reported. For NMR
also high detection limit has been reported [5]. List of pharmaceutical sample names and
[18]
contained residual solvents is reported in Table 8 .
TABLE 8: LIST OF PHARMACEUTICAL SAMPLE NAMES AND CONTAINED
RESIDUAL SOLVENTS
Pharmaceutical sample Residual solvent Class
Lidocain Heptane 3
Ethyl aminoben Toluene 2
Antipyrine Methanol 2
Phenacetin Methanol, toluene 2, 2
Cimetidine Ethanol 3
Famotidine Methanol 2
carbamazepine Acetone 3

CONCLUSION:
Whenever organic solvents are used in the production of pharmaceutical products,
especially in the last processing steps, the content of residual solvent in the final product
should be analyzed. The complete removal of residual level of these solvents is



impracticable and traces always remain in the final products. The presence of these
residual solvents even in small amounts has a negative influence not only on the quality
of products but also on human health. Acceptability of residual solvents seems to be best
judged following the ICH residual solvent guideline which is adopted by the USP, EP
and JP; it classifies the solvent into four groups. In class 1 are included the most toxic
solvents which, unless strongly justified, should be avoided. For the toxic solvents of
class 2, the limits are expressed as concentrations (ppm) and additionally in the case of
known daily drug intake, by the very important ‘permitted daily exposure’ (PDE). The
class 3 includes the solvents with low toxic potential for which the general limit is set at
0.5%. The class 4 includes solvents for which no adequate toxicological data was found.
REFERENCES
1. Michulec M., Wardenki, W. Development of headspace solid- phase
microextraction-gas chromatography method for the determination of solvent
residues in edible oils and pharmaceuticals. J. Chromatogr 2005; 1071: 119-124.
2. Dwivedi A. M. Residual solvent analysis in pharmaceuticals. Pharmaceutical
technology 2002; 42-46.
3. Camarasu C. Unknown residual solvents identification in drug products by
headspace solid phase microextraction gas chromatography- mass spectroscopy.
Chromatographia 2002; 56: S131-S135.
4. Rocheleau M J. Measuring residual solvents in pharmaceutical samples using fast
gas chromatography techniques. J. Chromatogr. B 2004; 805: 77-86.
5. B’Hymer C. Residual solvent testing: A review of gas chromatographic and
alternative techniques, Pharm. Res. 2003; 20, 337-343.
6. Otero, R., Carrera, G., Static headspace gas chromatographic method for
quantitative determination of residual solvents in pharmaceutical drug substances
according to European pharmacopoeia requirements. J. Chromatogr. A 2004;
1057: 193-201.
7. ICH Q3(C). Impurities: residual solvents 1997.
8. Countrymen, S. Understanding the revision to USP monograph <467>: residual
solvents, phenomenex Inc. Torrance, CA, USA, 2007.
9. General chapters <466>. "Ordinary impurities" and <1086>, "Impurities in



official articles," in USP 28--NF 23. US Pharmacopoeia. 12601 Twin brook
Parkway, Rockville, Maryland 20852, USA, 2004.
10. European pharmacopoeia. Identification and control of residual solvents (2.4.24),
directorate for the quality of medicines of the council of Europe, Strasbourg,
France, 2005; 5th edition, pp. 96.
11. European Pharmacopoeia. General chapter 5.10, Control of impurities in
substances for pharmaceutical use and general monograph: 2034, substances for
pharmaceutical use, 2005;5th edition. pp 559-561, 586-587.
12. Morris, J. M . Regulation of residual solvents in medicinal products in the
European Union, Irish medicines board, 2007.
13. Japanese Pharmacopoeia. Residual solvent testing, society of Japanese
pharmacopoeia, 14th edition.
14. Pfizer centre source. Triamcinalone, Pfizer.inc 2004.
15. Ahuja S. Residual solvents. Handbook of modern pharmaceutical analysis. Marcel
Dekker publications, 2003; pp. 86-87.
16. Wood, D. C., Miller, J. M. Headspace liquid microextraction. LC-GC Europe
2004; 17: 573-579.
17. Ahuja S. Gas chromatography, Handbook of modern pharmaceutical analysis.
Marcel Dekker publications, 2003; pp.375-377.
18. Madichie C., Camarasu C. Recent progress in the determination of volatile
impurities in pharmaceuticals. Trends in analytical chemistry 2006; 25: 768-777.

For Correspondence:
M.Arul Selvan
Email: steaje@gmail.com


Stephen 205 (1)

More Related Content

What's hot

Viewers also liked

Similar to Stephen 205 (1)

More from farsiya

Stephen 205 (1)